What is the 13F Pro Quality Score for KYNB?

13F Pro ranks KYNTRA BIO, INC. (KYNB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KYNB's current score at https://13fpro.ai/research/KYNB (free sign-up required for the full ranking).

Where does 13F Pro source KYNB data?

All KYNTRA BIO, INC. fundamentals and ownership data come directly from SEC EDGAR. KYNTRA BIO, INC. files with the SEC under CIK 921299. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KYNB in?

KYNTRA BIO, INC. (KYNB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KYNB research updated on 13F Pro?

KYNB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

KYNTRA BIO, INC.(KYNB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 921299 KYNB stock profile & AI dashboard →

13F Pro Quality Score

60.7/100

Rank #835 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

99.5/100

Balance Sheet

99.9/100

Earnings Quality

30.0/100

Free Cash Flow

25.0/100

Institutional Flow

7.8/100

Revenue Scale

3.3/100

Dilution Risk

3.1/100

KYNB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for KYNTRA BIO, INC. (KYNB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYNB at 60.7/100 on a 32-signal composite quality model, placing it at rank #835 of 2,879 stocks — the top half of the AI-ranked universe. KYNB scores in the top quartile across balance sheet strength (99.9), profitability (99.5), revenue growth (97.5). Areas of concern include revenue scale (3.3) and institutional flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), KYNTRA BIO, INC. reports quarterly revenue of $3.7M, net income of $-15.2M, free cash flow of $-13.9M. Top institutional holders of KYNB by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. KYNB trades on the Nasdaq exchange and files with the SEC under CIK 921299. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KYNTRA BIO, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$3.7M

Net Income

Q1 2026

$-15.2M

Free Cash Flow

Q1 2026

$-13.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-36.7% YoY

$29.6MFY 2024

FY18 $213.0MFY22 $140.7MFY23 $46.8MFY24 $29.6M

Net Income

+83.3% YoY

$-47.6MFY 2024

FY18 $-86.4MFY22 $-293.7MFY23 $-284.2MFY24 $-47.6M

Operating Income

+53.4% YoY

$-150.4MFY 2024

FY18 $-86.7MFY22 $-301.0MFY23 $-322.7MFY24 $-150.4M

EPS (Diluted)

-307.2% YoY

$-11.89FY 2024

FY18 —FY22 $-3.14FY23 $-2.92FY24 $-11.89

Total Assets

-49.3% YoY

$214.5MFY 2024

FY18 $880.6MFY22 $610.1MFY23 $423.5MFY24 $214.5M

Op. Cash Flow

+56.2% YoY

$-138.0MFY 2024

FY18 $-76.1MFY22 $-145.9MFY23 $-315.0MFY24 $-138.0M

Metric	FY 2024	FY 2023	FY 2022	FY 2018	FY 2017	FY 2016
Revenue	$29.6M -36.7%	$46.8M -66.7%	$140.7M -33.9%	$213.0M +62.6%	$131.0M -28.5%	$183.2M
Net Income	$-47.6M +83.3%	$-284.2M +3.2%	$-293.7M -239.8%	$-86.4M +28.5%	$-120.9M -108.2%	$-58.1M
Operating Income	$-150.4M +53.4%	$-322.7M -7.2%	$-301.0M -247.2%	$-86.7M +26.1%	$-117.3M -134.4%	$-50.0M
EPS (Diluted)	$-11.89 -307.2%	$-2.92 +7.0%	$-3.14	—	—	—
Total Assets	$214.5M -49.3%	$423.5M -30.6%	$610.1M -30.7%	$880.6M -2.0%	$898.6M +91.4%	$469.6M
Operating Cash Flow	$-138.0M +56.2%	$-315.0M -115.9%	$-145.9M -91.7%	$-76.1M -14.5%	$-66.5M -1035.7%	$7.1M

AI Insight: KYNB Financial Trends

KYNB collapsed from $81M quarterly revenue to $1–4M by 2025, with a one-time $201M gain in Q3 2025 masking persistent operating losses and negative equity of $44M.

• Revenue plummeted 95% from $81M in Q2 2024 to $1–4M in 2025–2026, signaling near-total business deterioration.

• Operating income remained negative every quarter from Q3 2024 onward, ranging from −$5M to −$92M; no path to profitability evident.

• Equity swung from −$232M to −$44M following Q3 2025's $201M net income, but reverted to −$44M by Q1 2026 as losses resumed.

⚠ Q3 2025 net income of $201M was a one-time event; underlying operational cash flow was −$2M, indicating unsustainable gain source.

⚠ Negative equity persists at −$44M in Q1 2026; balance sheet remains insolvent without material asset recovery or capital raise.

⚠ Operating cash flow turned negative again (−$14M in Q1 2026) after brief positive quarters; liquidity trend deteriorating.

AI Insight: KYNB Ratio Trends

KYNB's profitability has collapsed into persistent negative returns, with ROA deteriorating to -55.5% in Q1 2026.

• ROA swung from +33.5% in Q4 2024 to -55.5% in Q1 2026, signaling severe operational losses.

• NPM spiked to +169.4% in Q1 2025 but data gaps suggest inconsistent profitability thereafter.

⚠ ROIC turned negative at -37.3% in Q3 2025; company destroying shareholder capital.

⚠ OpMargin and NPM largely absent from recent quarters; opacity around earnings quality.

Get alerted when KYNB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for KYNTRA BIO, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KYNB

ARMISTICE CAPITAL, LLC
$2.7M400,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1M156,607 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$606.1K89,400 sh
BlackRock, Inc.
$571.8K84,331 sh
TWO SIGMA INVESTMENTS, LP
$335.7K49,511 sh
GEODE CAPITAL MANAGEMENT, LLC
$311.9K45,998 sh
HighTower Advisors, LLC
$269.5K39,744 sh
UBS Group AG
$187.1K27,591 sh
RENAISSANCE TECHNOLOGIES LLC
$186.3K27,481 sh
VANGUARD FIDUCIARY TRUST CO
$162.3K23,942 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$2.7M	400,000
VANGUARD CAPITAL MANAGEMENT LLC	$1.1M	156,607
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$606.1K	89,400
BlackRock, Inc.	$571.8K	84,331
TWO SIGMA INVESTMENTS, LP	$335.7K	49,511
GEODE CAPITAL MANAGEMENT, LLC	$311.9K	45,998
HighTower Advisors, LLC	$269.5K	39,744
UBS Group AG	$187.1K	27,591
RENAISSANCE TECHNOLOGIES LLC	$186.3K	27,481
VANGUARD FIDUCIARY TRUST CO	$162.3K	23,942

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KYNB on your watchlist

Track score changes the day KYNTRA BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KYNB a good stock to buy?

13F Pro's AI-powered analysis of KYNTRA BIO, INC. (KYNB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYNB are available on the KYNB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KYNB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYNB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KYNTRA BIO, INC.'s investment landscape.